Vol. 3 No. 3 (2023)
Reimbursement Recommendations

Finerenone (Kerendia)

decorative image

Published March 27, 2023

Key Messages

  • CADTH recommends that Kerendia be reimbursed by public drug plans as an adjunct to standard-of-care therapy in adult patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease (ESKD) and a sustained decrease in estimated glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure, if certain conditions are met.
  • Kerendia should only be covered to treat patients with CKD and T2D, with eGFR levels of at least 25 mL/min/1.73 m2, and have too much albumin in their urine. Kerendia should not be covered for patients with chronic heart failure or who are being treated with a mineralocorticoid receptor antagonist (e.g., spironolactone).
  • Kerendia should only be reimbursed if prescribed in consultation with a nephrologist with experience in diagnosing and managing patients with CKD and T2D and if the cost of Kerendia is reduced.